Flexshares Listed Private Equity Esg Ucits Etf (FLPE) News

Equillium to be included in the Russell Microcap® Index

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and...

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and...

Form 8-K - Current report

Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata

20% of all subjects that completed the 24-week treatment period achieved SALT ≤ 20 29% of completed subjects with moderate to severe disease...

Equillium to Present at the Jefferies Global Healthcare Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

More than 100 patients enrolled from over 100 clinical trial sites active in 12 countries Delivery of the interim data review to Ono...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights

$32.3 million cash balance at the end of Q1 2024 expected to provide cash runway into 2H 2025 Announced positive topline data from Phase 1b...

Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists

CD6 contributes to cell adhesion/migration both through direct ligand interactions with activated leukocyte cell adhesion molecule (ALCAM) and...

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and...

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis

Topline data delivered to Ono Pharmaceutical, representing the first of two data sets that will trigger Ono’s option exercise decision for...

Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights

$40.9 million cash balance at the end of 2023 expected to provide cash runway into 2H 2025 Completed enrollment of Phase 2 clinical study of...

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and...